WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H563010
CAS#: 1233923-95-9
Description: A457 is a prokineticin receptor antagonist.
Hodoodo Cat#: H563010
Name: A457 Antagonist
CAS#: 1233923-95-9
Chemical Formula: C26H33ClN2O3
Exact Mass: 456.22
Molecular Weight: 457.010
Elemental Analysis: C, 68.33; H, 7.28; Cl, 7.76; N, 6.13; O, 10.50
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: A457; A-457; A 457; A457 Antagonist;
IUPAC/Chemical Name: 1-Benzyl-pyrrolidine-3-carboxylic acid (9-chloro-3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-ylmethyl)-isobutyl-amide
InChi Key: IOXBZEKQVLIIQH-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H33ClN2O3/c1-19(2)15-29(17-21-13-23(27)25-24(14-21)31-11-6-12-32-25)26(30)22-9-10-28(18-22)16-20-7-4-3-5-8-20/h3-5,7-8,13-14,19,22H,6,9-12,15-18H2,1-2H3
SMILES Code: O=C(C1CN(CC2=CC=CC=C2)CC1)N(CC3=CC(Cl)=C4OCCCOC4=C3)CC(C)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 457.01 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Deihim B, Hassanzadeh M, Shafiei-Jandaghi NZ, Amanlou M, Douraghi M. Characterization of the DNA mismatch repair proteins MutS and MutL in a hypermutator Acinetobacter baumannii. Microb Pathog. 2017 Dec;113:74-84. doi: 10.1016/j.micpath.2017.10.001. Epub 2017 Oct 5. PubMed PMID: 28988868.
2: Li M, Wu H, Yang Q, Ke H, Yin B, Shi Q, Wang W, Wei Q, Xie G, Chen S. Experimental and Theoretical Interpretation on the Magnetic Behavior in a Series of Pentagonal-Bipyramidal Dy(III) Single-Ion Magnets. Chemistry. 2017 Dec 14;23(70):17775-17787. doi: 10.1002/chem.201703755. Epub 2017 Nov 8. PubMed PMID: 28984390.
3: Graham C, Knox H, Hess LM, Jen M, Cuyun Carter G, Chandrawansa K, Boye M. Cost-Effectiveness In The Second-Line Treatment Of Non-Small Cell Lung Cancer (Nsclc) In The Us. Value Health. 2015 Nov;18(7):A457-8. doi: 10.1016/j.jval.2015.09.1174. Epub 2015 Oct 20. PubMed PMID: 26532571.
4: Dorey J, Disset A, Elmoctar Neine M, Plun-Favreau J, Toumi M. A Cost-Effectiveness Analysis Of A Genomic Test Compared To Standard Of Care In Breast Cancer Patients In France. Value Health. 2015 Nov;18(7):A457. doi: 10.1016/j.jval.2015.09.1172. Epub 2015 Oct 20. PubMed PMID: 26532570.
5: Mennini FS, Bianic F, Baio G, Largeron N, Plazzotta G, Rinaldi A, De Waure C, Bonanni P. Estimating The Cost-Effectiveness Profile Of A Vaccination Programme With A Nine-Valent Hpv Vaccine In Italy. Value Health. 2015 Nov;18(7):A457. doi: 10.1016/j.jval.2015.09.1171. Epub 2015 Oct 20. PubMed PMID: 26532569.
6: Aiello A, Daniel F, D'Ausilio A, Snedecor SJ, Toumi M. Cost-Effectiveness Of Nilotinib In Patients With Chronic Myeloid Leukaemia Eligible To Start The Treatment-Free Remission Phase In Italy. Value Health. 2015 Nov;18(7):A457. doi: 10.1016/j.jval.2015.09.1170. Epub 2015 Oct 20. PubMed PMID: 26532568.
7: Gourzoulidis G, Kourlaba G, Apostolidis J, Lyman GH, Villa G, Papagiannopoulou V, Tritaki G, Maniadakis N. Cost-Effectiveness Analysis Of Granulocyte Colony-Stimulating Factors For The Prophylaxis Of Chemotherapy-Induced Febrile Neutropenia In Patients With Non-Hodgkin's Lymphoma In Greece. Value Health. 2015 Nov;18(7):A457. doi: 10.1016/j.jval.2015.09.1173. Epub 2015 Oct 20. PubMed PMID: 26532567.
8: Zhang H, Yue L, Chen Y, Ding H, Zhao K, Montgomery W. Medication Usage Pattern, Health Resource Utilization and Economic Burden for Patients with Mdd in Beijing, China. Value Health. 2014 Nov;17(7):A457. doi: 10.1016/j.jval.2014.08.1256. Epub 2014 Oct 26. PubMed PMID: 27201275.
9: Pletscher M, Mattli R, Reich O, Von Wyl A, Wieser S. The Societal Costs of Schizophrenia in Switzerland. Value Health. 2014 Nov;17(7):A457. doi: 10.1016/j.jval.2014.08.1253. Epub 2014 Oct 26. PubMed PMID: 27201274.
10: Shei A, Hirst M, Kirson NY, Enloe CJ, Birnbaum HG, Dunlop W. A Model to Estimate the Health System Burden of Prescription Opioid Abuse in Europe. Value Health. 2014 Nov;17(7):A457. doi: 10.1016/j.jval.2014.08.1254. Epub 2014 Oct 26. PubMed PMID: 27201273.
11: Gupta S, Isherwood G, Jones K, Van Impe K. Productivity Loss and Resource Utilization in Individuals Providing Care for Adults with Schizophrenia in the 5eu. Value Health. 2014 Nov;17(7):A457. doi: 10.1016/j.jval.2014.08.1255. Epub 2014 Oct 26. PubMed PMID: 27201272.
12: Tockhorn A, Televantou F, Dilla T. Atomoxetine for the Treatment of Newly Diagnosed Adults with Adhd - a Cost Effectiveness Analysis in Spain. Value Health. 2014 Nov;17(7):A457. doi: 10.1016/j.jval.2014.08.1257. Epub 2014 Oct 26. PubMed PMID: 27201271.
13: Sapin C, Tempest MJ, Gaughran F, Beillat M, Robinson P, Treur M. Aripiprazole Once-Monthly is a Cost-Effective Therapeutic Option in the Maintenance Treatment of Schizophrenia: Results from a Markov Model. Value Health. 2014 Nov;17(7):A457-8. doi: 10.1016/j.jval.2014.08.1258. Epub 2014 Oct 26. PubMed PMID: 27201270.
14: Chen DN, Ma YT, Liu H, Zhou QY, Li JD. Functional rescue of Kallmann syndrome-associated prokineticin receptor 2 (PKR2) mutants deficient in trafficking. J Biol Chem. 2014 May 30;289(22):15518-26. doi: 10.1074/jbc.M114.556381. Epub 2014 Apr 21. PubMed PMID: 24753254; PubMed Central PMCID: PMC4140907.
15: Potera C. Still searching for better butter flavoring. Environ Health Perspect. 2012 Dec;120(12):A457. doi: 10.1289/ehp.120-a457. PubMed PMID: 23211186; PubMed Central PMCID: PMC3548289.
16: Guo ZY, Chang CC, Chang TY. Functionality of the seventh and eighth transmembrane domains of acyl-coenzyme A:cholesterol acyltransferase 1. Biochemistry. 2007 Sep 4;46(35):10063-71. Epub 2007 Aug 11. PubMed PMID: 17691824.
17: Fields S. New paint: no harm, no foul? Environ Health Perspect. 2003 Jul;111(9):A457. PubMed PMID: 12842791; PubMed Central PMCID: PMC1316932.
18: Guermonprez L, O'Regan S, Meunier FM, Morot-Gaudry-Talarmain Y. The neuronal choline transporter CHT1 is regulated by immunosuppressor-sensitive pathways. J Neurochem. 2002 Aug;82(4):874-84. PubMed PMID: 12358793.
19: Dooley EE. Rising from the ashes: NIEHS awards post-WTC grants. Environ Health Perspect. 2002 Aug;110(8):A457. PubMed PMID: 12199201; PubMed Central PMCID: PMC1240966.
20: Tack D, Dolatabadi D, Delcour C. [Image of the month. Coronary stenosis detected by multislice computerized tomography x-ray]. Rev Med Brux. 2001 Oct;22(5):A457-8. French. PubMed PMID: 11723789.